---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-021914"
form_type: "8-K"
ticker: "DYAI"
cik: "0001213809"
company_name: "DYADIC INTERNATIONAL INC"
filed_at: "2025-11-12T23:59:59+00:00"
generated_at: "2026-05-16T20:55:59.364364+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Dyadic International Reports Q3 2025 Financial Results and Strategic Progress

## Summary
- Cash, cash equivalents and investment-grade securities totaled $10.4 million as of September 30, 2025.
- Net loss for Q3 2025 increased to $1.976 million from $0.203 million a year ago.
- Completed strategic pivot to commercial focus; rebranded as Dyadic Applied BioSolutions.
- Secured ERS Genomics CRISPR license to optimize protein production.
- Received $1.5 million in milestone payments from Proliant for animal-free serum albumin.

## SEC filing metadata
- accession: 0001493152-25-021914
- form_type: 8-K
- ticker: DYAI
- cik: 0001213809
- company_name: DYADIC INTERNATIONAL INC
- filed_at: 2025-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1213809/000149315225021914/0001493152-25-021914-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1213809/000149315225021914/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-021914
- JSON: https://secwatch.observer/filing/0001493152-25-021914.json
- Plain text: https://secwatch.observer/filing/0001493152-25-021914.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.